PE
KYMR icon

Point72 Europe’s Kymera Therapeutics KYMR Stock Holding History

Point72 Europe’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$45K Buy
+796
New +$35.9K ﹤0.01% 381

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Point72 Europe's KYMR Position: Q3 2025 in Review

Point72 Europe opened a new position in Kymera Therapeutics (KYMR) in Q3 2025: 796 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #381 among its holdings.

210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Point72 Europe held 796 shares of Kymera Therapeutics worth $45K as of Q3 2025.
  • Kymera Therapeutics was a new Point72 Europe position in Q3 2025.
  • Kymera Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #381 holding.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.